Opportunity Information: Apply for RFA CE 16 003
Apply for RFA CE 16 003
- The HHS-CDC-HHSCDCERA in the health sector is offering a public funding opportunity titled "Research on Prescription Opioid Use, Opioid Prescribing, and Associated Heroin Risk." and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.136.
- This funding opportunity was created on Nov 20, 2015 and posted on Nov 20, 2015.
- Applicants must submit their applications by Feb 18, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $400,000.00 in funding.
- The number of recipients for this funding is limited to 2 candidate(s).
- Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Research on Prescription Opioid Use, Opioid Prescribing, and Associated Heroin Risk" (Funding Opportunity Number RFA CE 16 003) is a CDC-funded cooperative agreement designed to support research that clarifies how prescription opioid pain relievers are connected to heroin use and heroin overdose risk. The central aim is to generate actionable evidence that can inform public health practice and policy during a period when opioid misuse and heroin-related harms were rapidly increasing. The CDC is looking for studies that can move beyond broad correlations and instead describe patterns, transitions, and risk pathways that link prescription opioid exposure, misuse behaviors, and downstream heroin outcomes.
The opportunity is structured around two distinct research priorities, and applicants are expected to submit a single application that addresses either Priority 1 or Priority 2, not both. Priority 1 focuses on understanding patterns of prescription opioid pain reliever use and misuse, with particular attention to how and why some individuals transition from misusing prescription opioids to using heroin. In practical terms, this line of research might examine trajectories of drug use over time, the circumstances that precede a switch to heroin (such as changes in access, price, formulation changes, or tolerance and dependence), and the characteristics of populations most likely to experience this transition. The goal is to describe the transition process with enough detail that prevention strategies can be better targeted, timed, and designed.
Priority 2 centers on prescribing and overdose outcomes. Under this priority, the research question is whether opioid prescribing itself is a risk factor for heroin overdose, and whether policies and interventions intended to reduce inappropriate prescribing are associated with changes in heroin overdose risk. This includes examining the real-world effects of prescribing-related strategies such as guidelines, insurer and pharmacy policies, prescribing limits, pain clinic regulations, prescription drug monitoring program approaches, and other efforts intended to curb unsafe prescribing. A key theme here is assessing whether such strategies are associated with unintended consequences (for example, changes in drug supply or behavior that might increase heroin risk) or, alternatively, whether they reduce overall overdose risk. The emphasis is on evaluating risk associations and policy impacts using rigorous analytic approaches.
Administratively, this is a discretionary funding opportunity offered by the U.S. Department of Health and Human Services through the Centers for Disease Control and Prevention (Agency: HHS-CDC-HHSCDCERA). The funding mechanism is a cooperative agreement, which typically indicates substantial involvement or partnership from the funding agency during the project period, such as collaboration on study design elements, data considerations, dissemination, or coordination with broader CDC objectives. The program is categorized under Health, and it is associated with CFDA number 93.136.
The maximum award amount listed is $400,000, and the CDC expected to make two awards under this announcement. Eligibility is described as unrestricted, meaning it is open to a wide range of applicant entity types, subject to any specific eligibility clarifications that may appear in the full announcement. Key dates show the opportunity was posted and created on November 20, 2015, with an original and current closing date of February 18, 2016.
Overall, the grant is aimed at producing evidence that helps public health officials, clinicians, and policymakers understand the relationship between prescription opioid exposure and heroin-related harms. Whether an applicant chooses Priority 1 or Priority 2, the work is intended to clarify causal pathways and population-level impacts so that opioid-related interventions can reduce harm without inadvertently increasing risk for heroin use or overdose.
Frequently Asked Questions (FAQs)
What is the title of this grant opportunity?
The opportunity is titled "Research on Prescription Opioid Use, Opioid Prescribing, and Associated Heroin Risk."
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is RFA CE 16 003.
Which federal agency is offering this opportunity?
This is a U.S. Department of Health and Human Services opportunity offered through the Centers for Disease Control and Prevention (CDC), listed as HHS-CDC-HHSCDCERA.
What type of funding mechanism is being used?
The award mechanism is a cooperative agreement.
What does it mean that this is a cooperative agreement?
Based on the description provided, a cooperative agreement typically indicates substantial involvement by the CDC during the project period, such as collaboration related to study design elements, data considerations, dissemination, or coordination with broader CDC objectives.
What is the overall purpose of this grant?
The purpose is to support research that clarifies how prescription opioid pain relievers are connected to heroin use and heroin overdose risk, producing actionable evidence that can inform public health practice and policy.
What is the central aim of the research supported by this opportunity?
The central aim is to generate evidence that goes beyond broad correlations by describing patterns, transitions, and risk pathways linking prescription opioid exposure and misuse behaviors to downstream heroin outcomes, including overdose risk.
What are the main research priorities under this opportunity?
There are two distinct research priorities: Priority 1 focuses on patterns of prescription opioid use/misuse and transitions to heroin use, and Priority 2 focuses on prescribing and heroin overdose outcomes, including the impact of prescribing-related policies and interventions.
Do applicants submit one application for both priorities or choose one?
Applicants are expected to submit a single application that addresses either Priority 1 or Priority 2, not both.
What is Priority 1 focused on?
Priority 1 focuses on understanding patterns of prescription opioid pain reliever use and misuse, with particular attention to how and why some individuals transition from misusing prescription opioids to using heroin.
What kinds of research questions fit under Priority 1?
Priority 1 research may examine trajectories of drug use over time, circumstances that precede switching to heroin (for example, changes in access, price, formulation changes, or tolerance and dependence), and characteristics of populations most likely to make this transition.
What is the intended outcome of Priority 1 research?
The goal is to describe the transition process in enough detail that prevention strategies can be better targeted, timed, and designed.
What is Priority 2 focused on?
Priority 2 centers on prescribing and overdose outcomes, including whether opioid prescribing itself is a risk factor for heroin overdose and whether policies and interventions aimed at reducing inappropriate prescribing are associated with changes in heroin overdose risk.
What kinds of policies or interventions are mentioned under Priority 2?
The opportunity description mentions guidelines, insurer and pharmacy policies, prescribing limits, pain clinic regulations, prescription drug monitoring program (PDMP) approaches, and other efforts intended to curb unsafe prescribing.
What kinds of impacts does Priority 2 emphasize evaluating?
Priority 2 emphasizes assessing risk associations and policy impacts, including whether prescribing-related strategies have unintended consequences that might increase heroin risk or whether they reduce overall overdose risk.
Why does this opportunity emphasize moving beyond broad correlations?
The CDC is seeking studies that describe specific patterns, transitions, and risk pathways linking prescription opioid exposure and misuse to heroin-related outcomes, rather than relying only on general associations.
What category is this program listed under?
The program is categorized under Health.
What CFDA number is associated with this opportunity?
The opportunity is associated with CFDA number 93.136.
What is the maximum award amount?
The maximum award amount listed is $400,000.
How many awards did the CDC expect to make?
The CDC expected to make two awards under this announcement.
Who is eligible to apply?
Eligibility is described as unrestricted, meaning it is open to a wide range of applicant entity types, subject to any specific eligibility clarifications that may appear in the full announcement.
When was the opportunity posted and created?
The opportunity was posted and created on November 20, 2015.
What was the application closing date?
The original and current closing date listed is February 18, 2016.
What public health problem is this funding opportunity responding to?
The opportunity is framed around a period when opioid misuse and heroin-related harms were rapidly increasing, and it aims to inform public health practice and policy to reduce those harms.
How is "actionable evidence" described in the opportunity summary?
Actionable evidence, as described, is evidence that can inform public health practice and policy by clarifying causal pathways, transition patterns, and population-level impacts related to prescription opioid exposure, misuse, and heroin-related outcomes.
What kinds of downstream outcomes are explicitly mentioned?
The description explicitly mentions heroin use and heroin overdose risk as downstream outcomes of interest.
What is the emphasis regarding prevention and policy implications?
Across both priorities, the emphasis is on generating evidence that helps officials, clinicians, and policymakers reduce harm from opioid-related interventions without inadvertently increasing risk for heroin use or overdose.
Browse more opportunities from the same category: Health
Next opportunity: Beginning Farmer and Rancher Development Program
Previous opportunity: Michigan Lupus Epidemiology and Surveillance (MILES) Program Longitudinal Cohort Study
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CE 16 003
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CE 16 003) also looked into and applied for these:
| Funding Opportunity |
|---|
| Centers for Disease Control and Prevention Natural History and Prevention of Viral Hepatitis among Alaska Natives Project. Apply for RFA PS 13 00104CONT16 Funding Number: RFA PS 13 00104CONT16 Agency: HHS-CDC-HHSCDCERA Category: Health Funding Amount: Case Dependent |
| Supporting Sustainable Implementation of HIV and TB Services for Epidemic Control in The Republic of Mozambique under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH16 1634 Funding Number: CDC RFA GH16 1634 Agency: HHS-CDC-CGH Category: Health Funding Amount: $165,000,000 |
| Provision of comprehensive HIV/AIDS services and developing national capacity to manage HIV/AIDS programs in the Republic of Uganda Apply for CDC RFA GH12 121304CONT16 Funding Number: CDC RFA GH12 121304CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Availability of Administrative Supplements to NIGMS Predoctoral Training Grants (Admin Supp) Apply for PA 16 060 Funding Number: PA 16 060 Agency: HHS-NIH11 Category: Health Funding Amount: $80,000 |
| Screening, Brief Intervention, and Referral to Treatment (SBIRT) Health Professions Student Training (SBIRT- Student Training) Apply for TI 16 002 Funding Number: TI 16 002 Agency: HHS-SAMHS Category: Health Funding Amount: $290,000 |
| Risk of Adolescence and Injury in HIV Susceptibility (RAIS) (R01) Apply for RFA AI 15 058 Funding Number: RFA AI 15 058 Agency: HHS-NIH11 Category: Health Funding Amount: $400,000 |
| Supporting Maternal and child Health Activities in Ethiopia Apply for RFI 663 16 EPCMD Funding Number: RFI 663 16 EPCMD Agency: USAID-ETH Category: Health Funding Amount: $120,000,000 |
| Guidelines for Women’s Preventive Services Apply for HRSA 16 057 Funding Number: HRSA 16 057 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Discovery/Development of Novel Therapeutics for Eukaryotic Pathogens (R21/R33) Apply for RFA AI 15 054 Funding Number: RFA AI 15 054 Agency: HHS-NIH11 Category: Health Funding Amount: $200,000 |
| Supporting the Implementation and Expansion of High Quality, Sustainable and Comprehensive HIV Prevention, Care and Treatment Programs in Faith-Based Organization Facilities in the Republic of Kenya under the President’s Emergency Plan for AIDS Rel Apply for CDC RFA GH16 1620 Funding Number: CDC RFA GH16 1620 Agency: HHS-CDC-CGH Category: Health Funding Amount: $23,000,000 |
| Defeat Malaria Apply for RFI 482 16 000001 Funding Number: RFI 482 16 000001 Agency: USAID-GHA Category: Health Funding Amount: $32,000,000 |
| ATSDR’s Program to Promote Localized Efforts to Reduce Environmental Exposure (APPLETREE) Apply for CDC RFA TS14 140303CONT16 Funding Number: CDC RFA TS14 140303CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Research on the Epidemiology, Prevention, Vaccine Effectiveness and Treatment of Influenza and Other Respiratory Viruses in South Africa Apply for RFA IP 16 003 Funding Number: RFA IP 16 003 Agency: HHS-CDC-HHSCDCERA Category: Health Funding Amount: $5,000,000 |
| SUPPORTING THE GHANA HEALTH SERVICE (GHS) IN THE STRENGTHENING OF NATIONAL HEALTH MANAGEMENT SYSTEMS IN THE AREAS OF STRATEGIC INFORMATION SYSTEMS, BLOOD SAFETY, AND LABORATORY CAPACITY BUILDING UNDER THE PRESIDENT’S EMERGENCY PLAN FOR AIDS RELIEF Apply for CDC RFA PS10 10440501SUPP16 Funding Number: CDC RFA PS10 10440501SUPP16 Agency: HHS-CDC Category: Health Funding Amount: $3,500,000 |
| Building Capacity for Human Resources for Health in HIV/AIDS in the Republic of Kenya under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH16 1624 Funding Number: CDC RFA GH16 1624 Agency: HHS-CDC-CGH Category: Health Funding Amount: $3,200,000 |
| Improving the Capacity of University Based Medical Education and Superior Training Institutions to Provide High Quality Education in the Republic of Mozambique Under the President's Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH11 1159SUPP Funding Number: CDC RFA GH11 1159SUPP Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Pre-application: Stimulating Peripheral Activity to Relieve Conditions (SPARC): Foundational Functional Mapping of Neuroanatomy and Neurobiology of Organs (OT1) Apply for RFA RM 15 019 Funding Number: RFA RM 15 019 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Strengthening the National Institutes of Health in the Republic of Mozambique under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH11 1158SUPP Funding Number: CDC RFA GH11 1158SUPP Agency: HHS-CDC Category: Health Funding Amount: $5,251,408 |
| NEI Clinical Study Planning Grant Program (R34) Apply for PA 16 038 Funding Number: PA 16 038 Agency: HHS-NIH11 Category: Health Funding Amount: $150,000 |
| Novel Nucleic Acid Sequencing Technology Development - Direct to Phase II (R44) Apply for RFA HG 15 039 Funding Number: RFA HG 15 039 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CE 16 003", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.